/
CGTX
$1.09-$0.03 (-2.68%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$100.2M
89M shares
52-week range
$0.29 – $3.83
23% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.60%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-11.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $81.0K | $98.0K | $0 | $235.0K | $0 | $0 | $0 |
| Gross profit | −$81.0K | −$98.0K | $0 | −$235.0K | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $14.4M | $12.9M | $18.6M | $30.3M | $37.2M | $41.7M | $37.2M |
| Operating income | −$17.8M | −$17.4M | −$28.6M | −$43.6M | −$50.7M | −$54.0M | −$47.8M |
| EBITDA | −$3.7M | −$6.0M | −$10.7M | −$21.1M | −$25.5M | −$33.7M | −$23.2M |
| Net income | −$7.0M | −$10.1M | −$11.7M | $757.0K | −$25.8M | −$34.0M | −$23.5M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.32 | -0.55 | -0.73 | -0.74 | -0.86 | -0.85 | -0.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $18M | $-0.32 | $-0.44–$-0.26 | 4 |
| 2027 | $42M | $-0.28 | $-0.36–$-0.19 | 3 |
| 2028 | $4M | $-0.43 | $-0.43–$-0.43 | 1 |
| 2029 | $45M | $-0.38 | $-0.38–$-0.38 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.60
Price
$1.09
Implied downside
-45%
Peer comparison
Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
www.cogrx.com- Employees
- 14
- IPO / List date
- Oct 8, 2021
- HQ
- PURCHASE, NY
Held by traders on TradeandTell
No one on the platform currently holds CGTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,117,136 | $848.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CGTX yet.
